Valeant – Financial Treason & Crime

Wayne Duggan, 16 February 2021

Investors who have owned stocks since 2016 generally have experienced some big gains. In fact, the SPDR S&P 500
SPY total return in the last five years is 131.9%. But there is no question some big-name stocks performed better than others along the way.

Valeant’s Downfall: One company that has been a disastrous investment in the last five years is health care company Bausch Health Companies Inc BHC 0.06% , formerly known as Valeant Pharmaceuticals. Not only has Bausch lagged the overall market in the last five years, Valeant represents one of the most infamous stock collapses in recent decades. Bausch produces pharmaceutical products and generic drugs. It is also the parent company of eye health products leader Bausch & Lomb.
Continue reading “Article: $1,000, 5 Years Later: Valeant’s Wild Ride To Bausch Health”

06/27/202006/27/2020

Subject: Fahmi Quadir

Subject of Interest

Founder & Chief Investment Officer at Safkhet Capital

Born in the USA to Bangladeshi parents. Left PhD track to do research at Deallus Consulting. Recruited by Michael Krensavage to be a short seller.

Central to the short selling of both Valeant and Wirecard. Has enjoyed a massive media elevation with no inquries into her connections to naked short sellers who destroyed both Valeant and Wirecard.

Website: https://safkhetcapital.com/

Comment: There is a new layer of naked short sellers and bashers on Wall Street that is connected to India, Pakistan, and Bangldesh. They are the new gang in town.

06/27/202006/27/2020

Article: The woman shaking up Wall Street

Article - Media

The woman shaking up Wall Street

Safi Thind, SquareMile, 7 February 2020

“Valeant had a certain reputation within the industry,” she says. “I knew it was already engaged in unethical, potentially fraudulent practice. Pharmaceuticals are a very established industry, when someone tries to disrupt it and post unusual numbers, there’s probably something wrong.”

Read full article.

09/13/201603/03/2021

Article: Jim Chanos: I’m still short Valeant and not about to quit

Article - Media, Publications

Jim Chanos: I’m still short Valeant and not about to quit

Tom DiChristopher, 13 September 2016

Short seller Jim Chanos on Tuesday said he is still short shares of Valeant Pharmaceuticals, and he’s not about to close out his bet against the drug company anytime soon.

“We started shorting the stock in the low $100s, added to it in the $200s, choked on it at $290 but stayed short and added to the stock as recently as early this year,” the Kynikos Associates founder told CNBC’s “Fast Money Halftime Report” on the sidelines of the Delivering Alpha conference in New York. Continue reading “Article: Jim Chanos: I’m still short Valeant and not about to quit”

03/21/201603/02/2021

Article: Drugmaker Valeant CEO leaving as investor Ackman joins board

Article - Media, Publications

Drugmaker Valeant CEO leaving as investor Ackman joins board

Reuters, 21 March 2016

Drugmaker Valeant Pharmaceuticals International Inc (>> Valeant Pharmaceuticals Intl Inc) (>> Valeant Pharmaceuticals Intl Inc) said on Monday its chief executive officer is leaving and billionaire investor William Ackman would join the board as it tries to clean up accounting problems and save its business.
(Reuters) – Drugmaker Valeant Pharmaceuticals International Inc (>> Valeant Pharmaceuticals Intl Inc) (>> Valeant Pharmaceuticals Intl Inc) said on Monday its chief executive officer is leaving and billionaire investor William Ackman would join the board as it tries to clean up accounting problems and save its business. Continue reading “Article: Drugmaker Valeant CEO leaving as investor Ackman joins board”

05/16/201403/02/2021

Article: Valeant accused of ‘aggressive accounting games’ by renowned short-seller Jim Chanos

Article - Media, Publications

Valeant accused of ‘aggressive accounting games’ by renowned short-seller Jim Chanos

Nicolas Van Praet, 16 May 2014

Valeant Pharmaceuticals International Inc. teamed up with respected activist Bill Ackman to buy Allergan Inc. in part to build its own legitimacy with investors after several periods of short-selling in Valeant stock in recent years. So far, however, the partnership has done little to silence the most vocal voices betting against Canada’s largest drug company. Continue reading “Article: Valeant accused of ‘aggressive accounting games’ by renowned short-seller Jim Chanos”